ARA-290 (aka Cibinetide) is a synthetic peptide derived from erythropoietin (EPO) designed to activate the innate repair receptor (IRR) and produce anti-inflammatory, neuroprotective, and tissue-repair effects without EPO’s red bood-cell-stimulating or pro-thrombotic actions.

Benefits

• Relief of neuropathic pain (especially small-fiber neuropathy)
• Strong anti-inflammatory
• Supports nerve repair/regeneration
• Restores immune balance in autoimmune disorders
• Tissue repair actions in injured, stressed, or ischemic tissues
• Provides adjunctive support for metabolic diseases like Type 2 diabetes, helping nerve complications, lipid/glucose improvements
• Does not produce clinically significant changes in electrolytes, liver, kidney, pancreas, erythrocytes, platelets, or leukocytes
• Improves lipid and glucose metabolism in diabetics

Interactions

• Concomitant use of strong immunosuppressants or biologic anti-inflammatory drugs may amplify immune modulation (caution advised)
• Agents that increase angiogenesis or that affect repair/vascular pathways may theoretically have additive or synergistic effects
• Given the repair/angiogenic axis, close monitoring of anticoagulent and antiplatelet medications is recommended
• Concomitant use of antidiabetic agents may require dose monitoring due to a risk of hypoglycemia

Contraindications

• Do not use if you are pregnant or breastfeeding
• Do not use if you determine that you are hypersensitive to this peptide
• Do not use if you have an active malignancy
• Do not use if you have uncontrolled cardiovascular disease or are at high risk of thrombosis